Aquaporin announces full-year 2024 results
Company announcement
No. 03/2025
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
"Notwithstanding the change in guidance published on
"In 2024, revenue decreased by 32% due to unexpected change in demand and the delay of a project. Strong cost control ensured improved EBIT (before special items) for the year, which allows
Business highlights
- Entered into strategic partnership with distributor Brenntag in APAC,
Turkey , andChina , strengtheningAquaporin's position to deliver advanced and sustainable wastewater treatment solutions. - Announced initial laboratory results for Aquaporin Inside® Generation 2, showing promising progress in membrane performance, ahead of pilot testing and scale up.
- Launched Brackish Water Reverse Osmosis CLEAR Series, designed to increase energy-efficiency for industry, municipalities, and businesses, in
China . - Secured new Brackish Water membrane orders in various geographies, including a milestone contract valued at
USD 300,000 for municipal drinking water treatment plant project inCentral Asia with CLEAR elements - Repeat sales of Forward Osmosis Essence-GO systems to various accounts.
- Launched water purifier, Rafine PRO, with leading technology company, Vestel, in
Turkey , offering high water contamination reduction rates with high-quality at-home purifier. - Completed successful Rights Issue raising gross proceeds of
DKK 172 million .
Financial highlights
- For the full year 2024, total revenue decreased by 32% to
DKK 40.6 million vs.DKK 59.5 million in 2023. The decrease was mainly driven by an unexpected change in demand fromAquaporin's largest key account in Drinking Water and a change in timing of a Forward Osmosis project. - In Industrial Water, revenue increased significantly by 192% to
DKK 10.5 million , while Drinking Water decreased by 55% toDKK 18 million andForward Osmosis Market Development decreased by 27% toDKK 12 million . - Gross profit margin amounted to 31% in 2024 (32% in 2023).
- Operating costs totaled
DKK 95.6 million , a decrease ofDKK 17.3 million compared to 2023. The cost decrease relates to organizational restructuring initiated in 2024, continued strong cost management focus, and actions taken to simplify the organization at an overall lower cost base. - EBIT (before special items) amounted to a loss of
DKK (83) million , compared to a loss ofDKK (90) million in 2023. - Cash and cash equivalents as of
December 31, 2024 amounted toDKK 77.3 million compared toDKK 2.8 million at year-end 2023.
Guidance 2025
For the full year 2025, we expect revenue in the range of
Webcast
On
For further information, please contact:
+45 53 55 55 19, investorrelations@aquaporin.com
About
Forward-looking statements
Matters discussed in this report may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as "believe", "expect", "anticipate", "intend", "estimate", "will", "may", "continue", "should", and similar expressions, as well as other statements regarding future events or prospects. Specifically, this report includes information with respect to projections, estimates, and targets that also constitute forward-looking statements. The forward-looking statements in this report are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies, and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, and other important factors include, among others: Limited experience in commercialization of the Company's products, failure to successfully implement strategies, dependence on third parties for manufacturing certain product components and the supply of certain raw materials, manufacturing disruptions, strategic collaboration, protection of the Company's intellectual property rights and other risks disclosed in Aquaporin's annual reports and company announcements. Such risks, uncertainties, contingencies, and other important factors could cause actual events to differ materially from the expectations, projections, estimates, and targets expressed or implied in this report by such forward-looking statements. The information, opinions, and forward-looking statements contained in this report speak only as at its date and are subject to change without notice.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/aquaporin-a-s/r/aquaporin-announces-full-year-2024-results,c4121540
The following files are available for download:
03-2025 |
|
894500AW5ZWMYUZN1V70-2024-12-31-0-en.zip |
|
https://news.cision.com/aquaporin-a-s/i/aquaporin-ar2024-cover-no-text,c3388681 |
Aquaporin AR2024 Cover no text |
https://mb.cision.com/Public/22362/4121540/be35a0cc57b5b685.pdf |
Annual Report 2024 |
https://mb.cision.com/Public/22362/4121540/baa5da2f04d5048a.pdf |
Remuneration Report 2024 |
View original content:https://www.prnewswire.co.uk/news-releases/aquaporin-announces-full-year-2024-results-302406829.html
